RETRACTED ARTICLE:FBXL5 targets cortactin for ubiquitination-mediated destruction to regulate gastric cancer cell migration

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8633-8638

  Cen, Gang ^a   Ding, Hong Hua ^a   Liu, Bin ^b   Wu, Wei Dong ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cortactin; FBXL5; Gastric cancer; Ubiquitylation

Indexed keywords

CORTACTIN; F BOX AND LEUCINE RICH REPEAT PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; SERINE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; CTTN PROTEIN, HUMAN; F BOX PROTEIN; FBXL5 PROTEIN, HUMAN; FLAVONOID; PROTEASOME; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; GASTRIC CANCER CELL LINE; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; METASTASIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; STOMACH CANCER; T LYMPHOCYTE; TRANSCRIPTION REGULATION; UBIQUITINATION; WESTERN BLOTTING; WILD TYPE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE;

BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CORTACTIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; F-BOX PROTEINS; FLAVONOIDS; HUMANS; MUTATION; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEOLYSIS; RNA INTERFERENCE; SERINE; STOMACH NEOPLASMS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84919844956     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2104-9     Document Type: TB

References (20)

1. Villanueva MT. Combination therapy: Update on gastric cancer in East Asia. Nat Rev Clin Oncol. 2011;8:690.
2. Smyth EC, Cunningham D. Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology. Nat Rev Clin Oncol. 2013;10:73–4.
3. Yakirevich E, Resnick MB. Pathology of gastric cancer and its precursor lesions. Gastroenterol Clin N Am. 2013;42:261–84.
4. Wu H, Parsons JT. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol. 1993;120:1417–26.
5. MacGrath SM, Koleske AJ. Cortactin in cell migration and cancer at a glance. J Cell Sci. 2012;125:1621–6.
6. Huang C, Liu J, Haudenschild CC, Zhan X. The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem. 1998;273:25770–6.
7. Zhao J, Wei J, Mialki R, Zou C, Mallampalli RK, Zhao Y. Extracellular signal-regulated kinase (erk) regulates cortactin ubiquitination and degradation in lung epithelial cells. J Biol Chem. 2012;287:19105–14.
8. Liu B, Zheng Y, Wang TD, Xu HZ, Xia L, Zhang J, et al. Proteomic identification of common scf ubiquitin ligase fbxo6-interacting glycoproteins in three kinds of cells. J Proteome Res. 2012;11:1773–81.
9. Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by f-box proteins. Nat Rev Mol Cell Biol. 2013;14:369–81.
10. Hsiang CY, Wu SL, Ho TY. Activation of activator protein 1 and extracellular signal-regulated kinases in human hepatocellular transformation. Tumour Biol J Int Soc Oncodev Biol Medic. 2004;25:313–20.
11. Folio C, Zalacain M, Zandueta C, Ormazabal C, Sierrasesumaga L, San Julian M, et al. cortactin (cttn) overexpression in osteosarcoma correlates with advanced stage and reduced survival. Cancer Biomark Sect A Dis Markers. 2011;10:35–41.
12. Ambrosio EP, Rosa FE, Domingues MA, Villacis RA, Coudry Rde A, Tagliarini JV, et al. cortactin is associated with perineural invasion in the deep invasive front area of laryngeal carcinomas. Hum Pathol. 2011;42:1221–9.
13. Ruiz JC, Walker SD, Anderson SA, Eisenstein RS, Bruick RK. F-box and leucine-rich repeat protein 5 (fbxl5) is required for maintenance of cellular and systemic iron homeostasis. J Biol Chem. 2013;288:552–60.
14. Moroishi T, Nishiyama M, Takeda Y, Iwai K, Nakayama KI. The fbxl5-irp2 axis is integral to control of iron metabolism in vivo. Cell Metab. 2011;14:339–51.
15. Vashisht AA, Zumbrennen KB, Huang X, Powers DN, Durazo A, Sun D, et al. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science. 2009;326:718–21.
16. Salahudeen AA, Thompson JW, Ruiz JC, Ma HW, Kinch LN, Li Q, et al. An e3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science. 2009;326:722–6.
17. Roskoski Jr R. Erk1/2 map kinases: Structure, function, and regulation. Pharmacolo Res Off J Ital Pharmacol Soc. 2012;66:105–43.
18. Kim SK, Abdelmegeed MA, Novak RF. The mitogen-activated protein kinase kinase (mek) inhibitor pd98059 elevates primary cultured rat hepatocyte glutathione levels independent of inhibiting mek. Drug Metab Dispos Biol Fate Chem. 2006;34:683–9.
19. Mezi S, Todi L, Orsi E, Angeloni A, Mancini P. Involvement of the src-cortactin pathway in migration induced by igf-1 and egf in human breast cancer cells. Int J Oncol. 2012;41:2128–38.
20. Nakane K, Fujita Y, Terazawa R, Atsumi Y, Kato T, Nozawa Y, et al. Inhibition of cortactin and sirt1 expression attenuates migration and invasion of prostate cancer du145 cells. Int J Urol Off J Jpn Urol Assoc. 2012;19:71–9.